New and investigational treatment options for ischemic stroke

Pharmacotherapy

Volumn 17, Issue 5 I, 1997, Pages 959-969

  Ryan, Melody ^a,d   Rhoney, Denise H ^c   Luer, Mark S ^b   Hatton, Jimmi ^a  

^a University of Kentucky   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c DETROIT RECEIVING HOSPITAL   (United States)

^d UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ALTEPLASE; APTIGANEL; CALCIUM CHANNEL BLOCKING AGENT; CITICOLINE; DEXTROMETHORPHAN; FIBRINOLYTIC AGENT; GANGLIOSIDE; GLUTAMATE RECEPTOR ANTAGONIST; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; LAZAROID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NIMODIPINE; SCAVENGER; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; FIBRINOLYTIC THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEUROPROTECTION; PATHOPHYSIOLOGY; REVIEW; STROKE; TREATMENT OUTCOME;

ANIMALS; CEREBROVASCULAR DISORDERS; DRUGS, INVESTIGATIONAL; FIBRINOLYTIC AGENTS; HUMANS;

EID: 0030778895     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Adams HP, Brott TG, Crowell RM, et al. Guidelines for the management of patients with acute ischemic stroke: a statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Stroke 1994;25:1901-14.
2. Heros RC. Stroke: early pathophysiology and treatment. Summary of the fifth annual decade of the brain symposium. Stroke 1994;25:1877-81.
3. Genentech, Inc. Activase (alteplase, recombinant) package insert. South San Francisco, CA; 1996 June.
4. Luer MS, Rhoney DH, Hughes M, Hatton J. New pharmacologic strategies in acute neuronal injury. Pharmacotherapy 1996;16(5):830-48.
5. Nilsson B, Norberg K, Nordstrom CH, Siesjo BK. Rate of energy utilization in the cerebral cortex or rats. Acta Physiol Scand 1997;93:569-71.
6. Nordstrom CH, Siesjo BK. Effects of pentobarbital in cerebral ischemia. I. Cerebral energy metabolism during pronounced incomplete ischemia. Stroke 1978;9:327-35.
7. Siesjo BK. Mechanisms of ischemic brain damage. Crit Care Med 1988;16:954-63.
8. Siesjo BK. Basic mechanisms of traumatic brain injury. Ann Emerg Med 1993;22:959-69.
9. McBurney RN, Daly D, Fischer JB, et al. New CNS-specific calcium antagonists. J Neurotrauma 1992;9(suppl 2):S531-43.
10. Hirsch JA, Gibson GE. Selective alteration of neurotransmitter release by low oxygen in vitro. Neurochem Res 1984;9:1039-49.
11. Bechman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990;87:1620-4.
12. Palmer RM, Moncada S. A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun 1989;158:348-52.
13. Garthwaite J, Garthwaite G, Palmer RM, Nocada S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 1989;172:413-16.
14. Anderson DK, Saunders RD, Demediuk P, et al. Lipid hydrolysis and peroxidation in injured spinal cord: partial protection with methylprednisolone or vitamin E and selenium. Cent Nerv Syst Trauma 1985;2:257-67.
15. Bazan NG, Rodriguez De Turco EB. Membrane lipids in the pathogenesis of brain edema: phospholipids and arachidonic acid, the earliest membrane components changed at the onset of ischemia. In: Cervos-Narro J, Ferszt R, eds. Advances of neurology. New York: Raven Press, 1980:197-204.
16. Chan PH, Yurko M, Fishman RA. Phospholipid degradation and cellular edema induced by free radicals in brain cortical slices. J Neurochem 1982;38:525-31.
17. Demediuk P, Faden AI, Romhanyi R, Vink R, McIntosh TK. Traumatic brain injury in the rat: effects on lipid metabolism, tissue magnesium, and water content. J Neurotrauma 1988;5:105-19.
18. Demediuk P, Daly MP, Faden AI. Changes in free fatty acids, phospholipids, and cholesterol following impact injury to the rat spinal cord. J Neurosci Res 1989;23:95-106.
19. Farooqui AA, Taylor WA, Horrocks LA. Phospholipases, lysophospholipases, and lipases and their involvement in various diseases. Neurochem Pathol 1987;7:99-128.
20. Horrocks LA, Demedirk P, Saunders RD, et al. The degradation of phospholipids, formation of metabolites of arachidonic acid, and demyelination following experimental spinal cord injury. Cent Nerv Syst Trauma 1985;2:115-20.
21. Armstead WM, Mirro R, Busija DW, Leffler CW. Postischemic generation of superoxide anion by newborn pig brain. Am J Physiol 1988;255:H401-3.
22. Cino M, Del Maestro RF. Generation of hydrogen peroxide by brain mitochondria: the effect of reoxygenation following postdecapitative ischemia. Arch Biochem Biophys 1989;269:623-38.
23. Hall Ed, Yonkers PA, Andrus PK, Cox JW, Anderson DK. Biochemistry and pharmacology of lipid antioxidants in acute brain and spinal cord injury. J Neurotrauma 1992;9:S425-42.
24. Schiller JH, Reilly PM, Bulkley GB. Antioxidant therapy. Crit Care Med 1993;21:S92-102.
25. Bannister JV, Bannister WH, Rotilio G. Aspects of the structure, function, and applications of superoxide dismutase. CRC Crit Rev Biochem 1987;22:111-80.
26. Forman HJ, Fisher AB. Antioxidant defenses. In: Gilbert DL, ed. Oxygen and living processes an interdisciplinary approach. New York: Springer-Verlag, 1981:235-49.
27. Flohe L. Glutathione peroxidease brought into focus. In: Pryor WA, ed. Free radicals in biology, vol IV. New York: Academic Press, 1980:223-54.
28. Packer JE, Slater TF, Wilson RI. Direct observation of a free radical interaction between vitamin E and vitamin C. Nature 1979;278:737-8.
29. Witting LA. Vitamin E and lipid antioxidants in free-radical initiated reactions. In: Pryor WA, ed. Free radicals in biology, vol IV. New York: Academic Press, 1980:295-319.
30. Hall ED. Intensive anti-oxidant pretreatment retards motor nerve degeneration. Brain Res 1987;713:175-8.
31. Hall ED, Braughler JM. Role of lipid peroxidation in post-traumatic spinal cord degeneration: a review. Cent Nerv Syst Trauma 1986;3:281-94.
32. Pietronigro DD, Hovsepian M, Demopoulos HB, Flamm ES. Loss of ascorbic acid from injured feline spinal cord. J Neurochem 1983;41:1072-6.
33. Pietronigro DD, DeCrescito V, Tomasula JJ, Demopoulos HB, Flamm ES. Ascorbic acid: a putative biochemical marker of irreversible neurologic functional loss following spinal cord injury. Cent Nerv Syst Trauma 1985;2:85-92.
34. Wei EP, Christman CW, Kontos HA, Povlishock JT. Effects of oxygen radicals of cerebral arterioles. Am J Physiol 1985;248:H157-62.
35. Yoshida S, Inoh S, Asano T, et al. Effect of transient ischemia on fatty acids and phospholipids in the gerbil brain. Lipid peroxidation as a possible cause of postischemic injury. J Neurosurg 1980;53:323-31.
36. Bowes MP, Zivin JA, Rothlein R. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol 1993;119: 215-19.
37. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-7.
38. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;275:1017-25.
39. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632-40.
40. Haley EC, Levy DE, Brott TG, et al. Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992;23:641-5.
41. Hommel M, Boissel JP, Cornu C, et al. Termination of trial of streptokinase in severe acute ischaemic stroke [letter]. Lancet 1994;345:57.
42. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-14.
43. Haley EC, Brott TG, Sheppard MD, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993;24:000-4.
44. Fitt GJ, Farrar J, Baird AE, et al. Intra-arterial streptokinase in acute ischaemic stroke: a pilot study. Med J Aust 1993;159:331-4.
45. Mori E, Tabuchi M, Yoshida T, Yamadori A. Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery. Stroke 1988;19:802-12.
46. Zeumer H, Freitag HJ, Zanella F, Thie A, Arning A. Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plasminogen activator (r-TPA). Neuroradiology 1993;35:159-62.
47. Leach MJ, Swan JH, Eisenthal D, Dopson M, Nobbs M. BW619C89, a glutamate release inhibitor, protects against focal cerebral ischemic damage. Stroke 1993;24:1063-7.
48. Graham SH, Chen J, Lan J, Leach MJ, Simon RP. Neuroprotective effects of a use-dependent blocker of voltage-dependent sodium channels, BW619C89, in rat middle cerebral artery occlusion. J Pharmacol Exp Ther 1994;269:854-9.
49. De Ryck M, Keersmaekers R, Duytschaever H, et al. Lubeluzole protects sensorimotor function and reduces infarct size in a photochemical stroke model in rats. J Pharmacol Exp Ther 1996;279:748-58.
50. Aronowski J, Strong R, Grotta JC. Treatment of experiemental focal ischemia in rats with lubeluzole. Neuropharmacology 1996;35:689-93.
51. Aronowski J, Strong R, Grotta JC. Combined neuroprotection and reperfusion therapy for stroke: effect of lubeluzole and diaspirin cross-linked hemoglobin in experimental focal ischemia. Stroke 1996;27:1571-7.
52. Lesage AS, Peeters L, Leysen JE. Lubeluzole, a novel long-term neuroprotectant, inhibits the glutamate-activated nitric oxide synthase pathway. J Pharmacol Exp Ther 1996;279: 759-66.
53. Maiese K, TenBroeke M, Kue I. Neuroprotection of lubeluzole is mediated through the signal transduction pathways of nitric oxide. J Neurochem 1997;68:710-14.
54. Diener HC, Hacke W, Hennerici M, et al. Lubeluzole in acute ischemic stroke: a double-blind, placebo-controlled phase II trial. Stroke 1996;27:76-81.
55. Sugiyama A, Ni C, Arita J, et al. Effects of the antihypoxic and neuroprotective drug, lubeluzole, on repolarization phase of canine heart assessed by monophasic action potential recording. Toxicol Appl Pharmacol 1996;139:109-14.
56. Albers GW, Saenz RE, Moses JA. Tolerability of oral dextromethorphan in patients with a history of brain ischemia. Clin Neuropharm 1992;15:509-14.
57. Choi DW. Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res 1987;403:333-6.
58. George CP, Goldberg MP, Choi DW, Steinberg GK. Dextromethorphan reduces neocortical ischemic neuronal damage in vivo. Brain Res 1988;440:375-9.
59. Grotta J, Clark W, Coull B, et al. Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke: results of a phase IIa randomized trial. Stroke 1995;26:602-5.
60. Davis SM, Albers GW, Diener H, Lees KR, Norris J. Termination of acute stroke studies involving selfotel treatment. Lancet 1997;349:32.
61. Fisher M. Cerestat, (CNS 1102) a non-competitive NMDA antagonist, in ischemic stroke patients: dose-escalating safety study [abstr]. Cerebrovasc Dis 1994;4:245.
62. Muir KW, Lees KR. Clinical experience with excitatory amino acid antagonist drugs. Stroke 1995;26:503-13.
63. Olney JW. Neurotoxicity of NMDA receptor antagonists: an overview. Psychopharmacol Bull 1994;30:533-40.
64. Sharp FR, Butman M, Wang S, et al. Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PCP), MK801, and ketamine. J Neurosci Res 1992;33:605-16.
65. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992;258:597-603.
66. Cory-Slechta DA. The impact of NMDA receptor antagonists on learning and memory functions. Psychopharmacol Bull 1994;30:601-12.
67. Lehmann J, Chapman AG, Meldrum BS, Hutchison A, Tsai C, Wood PL. CGS 19755 is a potent and competitive antagonist at NMDA-type receptors. Eur J Pharmacol 1988;154:89-93.
68. Morimoto K, Katayama K, Inoue K, Sato K. Effects of competitive and noncompetitive NMDA receptor antagonists on kindling and LTP. Pharmacol Biochem Behav 1991;40:893-99.
69. Gelmers HJ, Gorter K, de Weerdt CJ, Weizer HJA. A controlled trial of nimodipine in acute ischemic stroke. N Engl J Med 1988;318:203-7.
70. Paci A, Ottaviano P, Trenta A, et al. Nimodipine in acute ischemic stroke: a double-blind controlled study. Acta Neurol Scand 1989;80:282-6.
71. Martinez-Villa E, Guillen F, Villanueva JA, et al. Placebo-controlled trial of nimodipine in the treatment of acute ischemic cerebral infarction. Stroke 1990;21:1023-8.
72. The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992;23:3-8.
73. TRUST Study Group. Randomized, double-blind, placebo-controlled trial of nimodipine in acute stroke. Lancet 1990;336:1205-9.
74. Germano A, d'Avella D, Cicciarello R, Hayes RL, Tomasello F. Blood-brain barrier permeability changes after experimental subarachnoid hemorrhage. Neurosurgery 1992;30:882-6.
75. Svennenholm L. Gangliosides - a new therapeutic agent against stroke and Alzheimer's disease. Life Sci 1994;25/26:2125-34.
76. Bassi S, Albizzati MG, Sbacchi M, Frattola L. Monosialoganglioside therapy in stroke. Stroke 1985;16:899-900.
77. Hoffbrand BI, Bingley PJ, Oppenhimer SM, Sheldon CD. Trial of ganglioside GM1 in acute stroke. J Neurol Neurosurg Psychiatry 1988;51:1213-14.
78. The SASS Investigators. Ganglioside GM1 in acute ischemic stroke: the SASS trial. Stroke 1994;25:1141-8.
79. Argentino C, Sacchetti ML, Toni D, et al. GM1 ganglioside therapy in acute ischemic stroke. Stroke 1989;20:1143-9.
80. Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease. Clin Pharmacokinet 1995;29:110-29.
81. Smith DH, Gennarelli TA, McIntosh TK. The potential of 21-aminosteroids (lazaroids) as neuroprotective therapies in CNS injury. CNS Drugs 1995;3:159-64.
82. Clark WM, Hotan T, Lauten JD, Coull BM. Therapeutic efficacy of tirilazad in experimental multiple cerebral emboli: a randomized, controlled trial. Crit Care Med 1994;22:1161-6.
83. Wilson JT, Bednar MM, McAuliffe TL, Raymond S, Gross CE. The effect of the 21-aminosteroid U74006F in a rabbit model of thromboembolic stroke. Neurosurg 1992;31:929-34.
84. Umemura K, Wada K, Uematsu T, Mizuno A, Nakashima M. Effect of 21-aminosteroid lipid peroxidation inhibitor, U74006F in the rat middle cerebral artery occlusion model. Eur J Pharmacol 1994;251:69-74.
85. Hellstrom HO, Wanhainen A, Valtysson J, Persson L, Hillered L. Effect of tirilazad mesylate given after permanent middle cerebral artery occlusion in rat. Acta Neurochir 1994;129:188-92.
86. Park EK, Hall ED. Dose-response analysis of the effect of 21-aminosteroid tirilazad mesylate (U-74006F) upon neurological outcome and ischemic brain damage in permanent focal cerebral ischemia. Brain Res 1994;645:157-63.
87. Fleishaker JC, Pearson PG, Wienkers LC, Pearson LK, Peters GR. Biotransformation of tirilazad in humans. 2. Effect of ketoconazole on tirilazad clearance and oral bioavailability. J Pharmacol Exp Ther 1996;277:991-8.
88. Fleishaker JC, Hulst LK, Peters GR. The effect of phenytoin on the pharmacokinetics of tirilazad mesylate in healthy male volunteers. Clin Pharmacol Ther 1994;56:389-97.
89. Drury I, Beydoun A. Seizure disorders of aging: differential diagnosis and patient management. Geriatrics 1993;48:52-8.
90. Hulst LK, Fleishaker JC, Peters GR, Harry JD, Wright DM, Ward P. Effect of age and gender on tirilazad pharmacokinetics in humans. Clin Pharmacol Ther 1994;55:378-84.
91. Wienkers LC, Steenwyk RC, Mizsak SA, Pearson PG. In vitro metabolism of tirilazad mesylate in male and female rats. Contribution of cytochrome P4502C11 and delta 4-5 alpha-reductase. Drug Metab Dispos 1995;23:383-92.
92. Tazaki Y, Sakai F, Otomo E, et al. Treatment of acute cerebral infarction with a choline precursor in a multicenter double-blind placebo-controlled study. Stroke 1988;19: 211-16.
93. Hazama T, Hasegawa T, Ueda S, Sakuma A. Evaluation of the effect of CDP-choline on poststroke hemiplegia employing a double-blind controlled trial: assessed by a new rating scale for recovery in hemiplegia. Int J Neurosci 1980;11:211-25.
94. Hess DC, Bhutwala T, Sheppard JC, Zhao W, Smith J. ICAM-1 expression on human brain microvascular endothelial cells. Neurosci Lett 1994;168;201-4.
95. Bowes MP, Zivin JA, Rothlein R. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol 1993;119: 215-19.
96. Wang X, Siren AL, Liu Y, Yue T, Barone FC, Feuerstein GZ. Upregulation of intercellular adhesion molecule 1 (ICAM-1) on brain microvascular endothelial cells in rat ischemic cortex. Mol Brain Res 1994;26:61-8.
97. Clark WM, Lauten JD, Woodward WR, Coull BM. Delayed ICAM-1 expression and macrophage infiltration in rat forebrain ischemia [abstr]. Stroke 1994;25:266.
98. Zhang RL, Chopp M, Li Y, et al. Anti-ICAM-1 antibody reduces ischemic cell damage after transient middle cerebral artery occlusion in the rat. Neurology 1994;44:1747-51.
99. Clark WM, Madden KP, Rothlein R, Zivin JA. Reduction of central nervous system ischemic injury by monoclonal antibody to intercellular adhesion molecule. J Neurosurg 1991;75:623-7.
100. Nakata N, Kato H, Kogure K. Protective effects of basic fibroblast growth factor against hippocampal neuronal damage following cerebral ischemia in the gerbil. Brain Res 1993;605:354-6.
101. Gluckman P, Klempt N, Guan J, et al. A role for IGF-1 in the rescue of CNS neurons following hypoxic-ischemic injury. Biochem Biophys Res Commun 1992;182:593-9.
102. Bergstedt K, Wielock T. Changes in insulin-like growth factor 1 receptor density after transient cerebral ischemia in the rat, lack of protection against ischemic brain damage following injection of insulin-like growth factor 1. J Cereb Blood Flow Metab 1993;13:895-8.
103. Zhu CZ, Auer RN. Intraventricular administration of insulin and IGF-1 in transient forebrain ischemia. J Cereb Blood Flow Metab 1994;14:237-42.
104. Adams HD, Brott TG, Furlan AJ, et al. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. Circulation 1996;94:1167-74.